| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Navidea Biopharmaceuticals, Inc. (AMEX: NAVB)
NAVB Technical Analysis
2
| As on 31st Oct 2017 NAVB Share Price closed @ 0.42 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.51 & Buy for SHORT-TERM with Stoploss of 0.41 we also expect STOCK to react on Following IMPORTANT LEVELS. |
NAVB Share Price
| Open | 0.43 | Change | Price | % |
| High | 0.45 | 1 Day | -0.01 | -2.33 |
| Low | 0.41 | 1 Week | 0.00 | 0.00 |
| Close | 0.42 | 1 Month | -0.01 | -2.33 |
| Volume | 282676 | 1 Year | -0.42 | -50.00 |
| 52 Week High 1.16 | 52 Week Low 0.29 | ||||
AMEX USA Most Active Stocks
| PAL | 0.05 | -50.00% |
| NGD | 3.29 | -6.80% |
| RBY | 0.03 | -70.00% |
| LODE | 0.12 | -7.69% |
| PBTH | 8.23 | 0.37% |
| GGR | 0.02 | 100.00% |
| VTG | 0.05 | -16.67% |
| SYRG | 8.13 | 0.87% |
| GSX | 0.02 | 0.00% |
| SHZ | 0.10 | -16.67% |
AMEX USA Top Gainers Stocks
AMEX USA Top Losers Stocks
| NAVB Daily Charts |
NAVB Intraday Charts |
Whats New @ Bazaartrend |
NAVB Free Analysis |
|
|
NAVB Important Levels Intraday
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| RESISTANCE | 0.46 |
| RESISTANCE | 0.44 |
| SUPPORT | 0.40 |
| SUPPORT | 0.38 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
NAVB Target for Month January
| 4th UP TARGET | 0.96 |
| 3rd UP TARGET | 0.79 |
| 2nd UP TARGET | 0.68 |
| 1st UP TARGET | 0.57 |
| 1st DOWN TARGET | 0.27 |
| 2nd DOWN TARGET | 0.16 |
| 3rd DOWN TARGET | 0.05 |
| 4th DOWN TARGET | -0.12 |
NAVB Weekly Target
| 4th UP TARGET | 0.00 |
| 3rd UP TARGET | 0.00 |
| 2nd UP TARGET | 0.00 |
| 1st UP TARGET | 0.00 |
| 1st DOWN TARGET | 0.00 |
| 2nd DOWN TARGET | 0.00 |
| 3rd DOWN TARGET | 0.00 |
| 4th DOWN TARGET | 0.00 |
NAVB Target for Year 2021
| 4th UP TARGET | 0 |
| 3rd UP TARGET | 0 |
| 2nd UP TARGET | 0 |
| 1st UP TARGET | 0 |
| 1st DOWN TARGET | 0 |
| 2nd DOWN TARGET | 0 |
| 3rd DOWN TARGET | 0 |
| 4th DOWN TARGET | 0 |
Navidea Biopharmaceuticals, Inc. ( AMEX USA Symbol : NAVB )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
NAVB Other Details
| Segment | EQ | |
| Market Capital | 274868832.00 | |
| Sector | Healthcare | |
| Industry | Medical Appliances & Equipment | |
| Offical website | > | |
NAVB Address
 |
5600 Blazer Parkway Suite 200 Dublin, OH 43017 United States Phone: 614-793-7500 Fax: 614-793-7522 |
|
NAVB Latest News
NAVB Business Profile
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision diagnostics and radiopharmaceutical agents. The companyÂ’s radiopharmaceutical development programs include Lymphoseek Injection, a receptor-targeted small-molecule radiopharmaceutical used in lymphatic mapping procedures, which are performed to evaluate breast cancer and melanoma; Manocept platform to target the CD206 mannose receptor expressed on macrophages; and NAV4694, an Fluorine-18 radiolabeled positron emission tomography imaging agent, which is used as an aid in the diagnosis of patients with signs or symptoms of cognitive impairment, such as AlzheimerÂ’s disease. Its radiopharmaceutical development programs also comprise NAV5001, an Iodine-123 radiolabeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of ParkinsonÂ’s disease and other movement disorders with potential use as a diagnostic aid in dementia; and NAV1800, a radiolabeled monoclonal antibody that is developed as a diagnostic aid for use during surgery to help surgeons locate occult or metastatic cancer, primarily colorectal cancer. Navidea Biopharmaceuticals, Inc. has research and development agreements with University of California, AstraZeneca AB, Alseres Pharmaceuticals, Inc., and The Ohio State University. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.
© 2005-2019 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
